Detalhe da pesquisa
1.
Regenerating islet-derived family member, 4 modulates multiple receptor tyrosine kinases and mediators of drug resistance in cancer.
Int J Cancer
; 130(6): 1251-63, 2012 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21445968
2.
A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non-small Cell Lung Cancer.
Clin Cancer Res
; 27(16): 4566-4573, 2021 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34108179
3.
Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin.
Breast Cancer Res
; 12(3): R32, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20525379
4.
Low-dose metronomic cyclophosphamide complements the actions of an intratumoral C-class CpG TLR9 agonist to potentiate innate immunity and drive potent T cell-mediated anti-tumor responses.
Oncotarget
; 10(68): 7220-7237, 2019 Dec 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-31921384
5.
Discovery and Optimization of HKT288, a Cadherin-6-Targeting ADC for the Treatment of Ovarian and Renal Cancers.
Cancer Discov
; 7(9): 1030-1045, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28526733
6.
Microarray analysis of primary endothelial cells challenged with different inflammatory and immune cytokines.
Cytokine
; 29(6): 256-69, 2005 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-15749026